Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29074286 | 0.85 | CALM1 (0.50) | CTRCGPR55CALM1MEN1ELANE | |
| SCHEMBL9945573 | 0.81 | ALDH1A1 (0.57) | ALDH1A1IDH1 | |
| SCHEMBL9945574 | 0.80 | TP53 (0.43) | CTRCGPR55CNR2CALM1MEN1 | |
| SCHEMBL8233984 | 0.80 | CALM1 (0.41) | CTRCLTA4HGPR55TEKCNR2 | |
| SCHEMBL13333915 | 0.79 | ALDH1A1 (0.42) | ALDH1A1KMT2AIDH1 | |
| SCHEMBL10006132 | 0.77 | CTRC (0.43) | CTRCGPR55CALM1ALDH1A1MEN1 | |
| SCHEMBL12849614 | 0.77 | TSHR (0.43) | CTRCCALM1MEN1ELANEKMT2A | |
| SCHEMBL15161586 | 0.76 | ABCG2 (0.41) | KDM4EALDH1A1POLBGAAMEN1 | |
| SCHEMBL8233981 | 0.73 | CALM1 (0.41) | CTRCGPR55CALM1MEN1ELANE | |
| SCHEMBL794 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946144-B2 | Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. (CA) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113333-A1 | PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | PGLS, BPGM, PAG1 | CTRC 4065/4885LTA4H 827/4885GPR55 2291/4885 |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | CTRC 2181/4885LTA4H 282/4885GPR55 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.